Celemics

Celemics Receivables

The Accounts Receivable of Celemics (331920.KQ) as of Oct 28, 2026 is 543.33 M KRW. In the previous year, Accounts Receivable was 649.08 M KRW — a change of -16.29% (lower).

Receivables

543.33 MKRW

YoY

-16.29%

Last updated:

Accounts Receivable of Celemics is 2024 543.33 M KRW. Accounts Receivable of Celemics was 2023 649.08 M KRW. It decreases by -16.29% lower compared to the previous year.

The Celemics Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
605.00 M KRW
Jan 1, 2018
1.44 B KRW
Jan 1, 2019
1.81 B KRW
Jan 1, 2020
1.29 B KRW
Jan 1, 2021
1.04 B KRW
Jan 1, 2022
906.27 M KRW
Jan 1, 2023
649.08 M KRW
Jan 1, 2024
543.33 M KRW
The Celemics Receivables history
YEARReceivablesYoY
543.33 MKRW-16.29%
649.08 MKRW-28.38%
906.27 MKRW-12.56%
1.04 BKRW-19.41%
1.29 BKRW-29.07%
1.81 BKRW+25.64%
1.44 BKRW+138.51%
605.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

Accounts Receivable of Celemics is 543.33 M KRW in 2024.

Accounts Receivable of Celemics changed from 649.08 M KRW to 543.33 M KRW, representing a -16.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Celemics since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Celemics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Celemics

All Key Metrics — Celemics